James Osborne, PharmD

Director, Field Medical Accounts
GSK US Medical Affairs

Poster(s):

• (311) Belantamab Mafodotin Individual Patient Dosing in Patients With Relapsed/Refractory Multiple Myeloma Treated in the Phase 3 DREAMM-7 and DREAMM-8 Clinical Trials
  Wednesday, October 29, 2025